Laboratorios Farmaceuticos Rovi Stock Analysis
| LABFF Stock | USD 90.61 0.00 0.00% |
Laboratorios Farmaceuticos holds a debt-to-equity ratio of 0.182. Laboratorios Farmaceuticos' financial risk is the risk to Laboratorios Farmaceuticos stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Laboratorios Farmaceuticos' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Laboratorios Farmaceuticos' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Laboratorios Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Laboratorios Farmaceuticos' stakeholders.
For many companies, including Laboratorios Farmaceuticos, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Laboratorios Farmaceuticos Rovi, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Laboratorios Farmaceuticos' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Laboratorios Farmaceuticos' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Laboratorios Farmaceuticos is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Laboratorios Farmaceuticos to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Laboratorios Farmaceuticos is said to be less leveraged. If creditors hold a majority of Laboratorios Farmaceuticos' assets, the Company is said to be highly leveraged.
Laboratorios Farmaceuticos Rovi is fairly valued with Real Value of 90.61 and Hype Value of 90.61. The main objective of Laboratorios Farmaceuticos pink sheet analysis is to determine its intrinsic value, which is an estimate of what Laboratorios Farmaceuticos Rovi is worth, separate from its market price. There are two main types of Laboratorios Farmaceuticos' stock analysis: fundamental analysis and technical analysis.
The Laboratorios Farmaceuticos pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Laboratorios Farmaceuticos' ongoing operational relationships across important fundamental and technical indicators.
Laboratorios |
Laboratorios Pink Sheet Analysis Notes
About 60.0% of the company outstanding shares are owned by corporate insiders. The company last dividend was issued on the 5th of July 2022. Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. Laboratorios Farmaceticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L. Laboratorios Farmaceuticos operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1852 people.The quote for Laboratorios Farmaceuticos Rovi is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Laboratorios Farmaceuticos Rovi contact Juan Encina at 34 91 021 30 00 or learn more at https://www.rovi.es.Laboratorios Farmaceuticos Investment Alerts
| Laboratorios Farmaceuticos generated a negative expected return over the last 90 days | |
| About 60.0% of the company outstanding shares are owned by corporate insiders |
Laboratorios Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Laboratorios Farmaceuticos's market, we take the total number of its shares issued and multiply it by Laboratorios Farmaceuticos's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Laboratorios Profitablity
The company has Profit Margin (PM) of 0.23 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.28.Technical Drivers
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Laboratorios Farmaceuticos, as well as the relationship between them.Laboratorios Farmaceuticos Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Laboratorios Farmaceuticos price series with the more recent values given greater weights.
Laboratorios Farmaceuticos Debt to Cash Allocation
Many companies such as Laboratorios Farmaceuticos, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Laboratorios Farmaceuticos Rovi has accumulated 52.52 M in total debt with debt to equity ratio (D/E) of 0.18, which may suggest the company is not taking enough advantage from borrowing. Laboratorios Farmaceuticos has a current ratio of 1.73, which is within standard range for the sector. Debt can assist Laboratorios Farmaceuticos until it has trouble settling it off, either with new capital or with free cash flow. So, Laboratorios Farmaceuticos' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Laboratorios Farmaceuticos sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Laboratorios to invest in growth at high rates of return. When we think about Laboratorios Farmaceuticos' use of debt, we should always consider it together with cash and equity.Laboratorios Farmaceuticos Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Laboratorios Farmaceuticos' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Laboratorios Farmaceuticos, which in turn will lower the firm's financial flexibility.About Laboratorios Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Laboratorios Farmaceuticos prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Laboratorios shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Laboratorios Farmaceuticos. By using and applying Laboratorios Pink Sheet analysis, traders can create a robust methodology for identifying Laboratorios entry and exit points for their positions.
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. Laboratorios Farmaceticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L. Laboratorios Farmaceuticos operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1852 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Laboratorios Farmaceuticos to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Complementary Tools for Laboratorios Pink Sheet analysis
When running Laboratorios Farmaceuticos' price analysis, check to measure Laboratorios Farmaceuticos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratorios Farmaceuticos is operating at the current time. Most of Laboratorios Farmaceuticos' value examination focuses on studying past and present price action to predict the probability of Laboratorios Farmaceuticos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratorios Farmaceuticos' price. Additionally, you may evaluate how the addition of Laboratorios Farmaceuticos to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |